SYGNIS AG: SYGNIS AG proposes at AGM change of name to Expedeon AG

PRESS RELEASE
30 May 2018
/

SYGNIS AG proposes at AGM change of name to Expedeon AG

- SYGNIS AG and its subsidiaries will be fully integrated and operating as Expedeon AG, following shareholder approval at the Annual General Meeting on 5 July 2018

- Change of name reflects both, the development of the Company into a global brand in the genomics, proteomics and immunology markets as well as its successful execution of the 'Grow, Buy and Build strategy'

Heidelberg, Germany and Cambridge, UK, 30 May 2018 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced on 28 May the agenda for its Annual General Meeting, to be held on 5 July 2018. The Management Board and the Supervisory Board of SYGNIS proposes to change the Company name from SYGNIS AG to Expedeon AG. This proposal follows the successful integration of the Group's subsidiaries under the Expedeon brand. The Company's shares will continue to be listed on the Regulated Market of the Frankfurt Stock Exchange's Prime Standard.

"In the past years, the Group has successfully grown through strategic, profitable acquisitions of companies with complementary products and technologies. The continuously growing product portfolio increases our market share, which is reflected in our strong revenue growth. The proposed Company name change is an important strategic step to support the strong umbrella brand Expedeon. Furthermore, the name change offers new perspectives for the Group to pursue through our 'Grow, Buy and Build-strategy' to establish a leading provider of solutions to address key challenges in molecular biology," said Dr. Heikki Lanckriet, CEO and CSO of SYGNIS AG.

Subject to shareholder approval, the corporate name change follows the integration of the Company's acquired subsidiaries Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific under the Expedeon brand and the recently completed acquisition of TGR Biosciences, as announced in March. As a fully integrated Company, Expedeon AG will continue to work towards expanding its market position with a broad commitment and a growing range of cutting-edge tools and customised services to further benefit the research community, worldwide. The combined product offering and the uniform, updated corporate identity is accessible via the website www.expedeon.com.

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)
Dr. Claudia Gutjahr-Loeser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group's cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###